UK to enter dedicated magnetic resonance imaging (MRI) race
This article was originally published in Clinica
The UK is about to enter the MRI market, many years after the country's scientists led early development of the technique. London-based InnerVision has developed a miniature system for orthopaedic studies, designed to relieve the burden of a busy MRI unit with a more cost-effective alternative.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.